Form 8-K MoonLake Immunotherapeut For: Sep 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Moonlake Immunotherapeutics (MLTX) PT Lowered to $12 at Clear Street
September 29, 2025 4:38 PM EDTClear Street analyst Kaveri Pohlman lowered the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $12.00 (from $108.00) while maintaining a Buy rating.
The analyst comments "We believe COSENTYXs approvaleven without statistically significant results in one of its P3 trials (Sunshine)serves as an encouraging... More
